春立醫療(01858.HK):史春生代行董事會祕書職責
格隆匯1月18日丨春立醫療(01858.HK)公吿,北京市春立正達醫療器械股份有限公司(以下簡稱“公司”)於2022年1月18日召開了第四屆董事會第十六次會議,會議審議通過了《關於指定高級管理人員代行董事會祕書職責的議案》。現將具體情況公吿如下:
公司已於2021年12月30日在上交所科創板上市,根據《上海證券交易所科創板股票上市規則》等有關規定,公司董事會指定公司副總經理史春生代行董事會祕書職責,代行時間不超過三個月,公司確定的董事會祕書史春生將盡快報名參加上交所組織的科創板董事會祕書培訓。公司將在史春生取得科創板董事會祕書資格證書,且其任職資格經過上交所審核無異議後,儘快完成董事會祕書的備案工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.